

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**EXAMINER
SIGNATURE**

~~DATE CONSIDERED~~

9/2/2005

SIGNATURE [Signature]

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds and Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Michael J. Elliott, et al.
Serial No.: 08/602,272
Filed: February 16, 1996
Exhibit A

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

| | |
|----------------------|---------------------------|
| Application Number | 08/602,272 |
| Filing Date | February 16, 1996 |
| First Named Inventor | Michael J. Elliott |
| Art Unit | 1642 |
| Examiner Name | K. Canella |
| Attorney Docket No. | 1481/65021/JPW/AJ M/CY |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-------------------|-----------------------|---|----------------|
| KAC | 2 | BERTINI, R., ET AL., "Depression Of Liver Drug Metabolism And Increase In Plasma Fibrinogen By Interleukin 1 And Tumor Necrosis Factor: A Comparison With Lymphotoxin And Interferon," <u>Int J. Immunopharmac.</u> (1988), 19(5):525-530 (EXHIBIT 2); | |
| | 3 | BERTINI, R., ET AL., "Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron," <u>J. Leukoc. Biol.</u> (1989), 46(3):254-62 (EXHIBIT 3); | |
| | 4 | GRESSER, I., ET AL., "Tumor necrosis factor induces acute phase proteins in rats," <u>J. Biol. Regul. Homeost. Agents</u> (1987), 1(4):173-6 (EXHIBIT 4); | |
| | 5 | NAWROTH, P., ET AL., "Tumor Necrosis Factor/Cachectin-Induced Intravascular Fibrin Formation In Meth A Fibrosarcomas," <u>J. Exp. Med.</u> (1988), 168:637-647 (EXHIBIT 5); | |
| | 6 | SEKUT, L., ET AL., "Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation," <u>Clin. Exp. Immunol.</u> (1995), 100(1):126-32 (EXHIBIT 6); | |
| | 7 | SORIA, J., ET AL., "Pentoxifylline, fibrinogen and leukocytes," <u>Blood Coagul. Fibrinolysis</u> (1990), 1(4-5):485-7 (EXHIBIT 7); | |
| | 8 | VAN DER POLL, T., ET AL., "Fibrinolytic Response to Tumor Necrosis Factor in Healthy Subjects," <u>J. Exp. Med.</u> (1991), 174:729-732 (EXHIBIT 8); | |
| | 9 | VAN HINSBERGH, V.W., ET AL., "Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products," <u>Blood</u> (1990), 76(11):2284-9 (EXHIBIT 9); and | |
| ✓ | 10 | ZABEL, P. et al., "Inhibition of endogenous TNF formation by pentoxifylline," <u>Immunobiology</u> (1993), 187(3-5):447-63, review (EXHIBIT 10). | |
| | | | |

EXAMINER
SIGNATURE*K. Canella*

DATE CONSIDERED

9/2/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.



| | | | | | | | |
|--|--|--|------|---|-------|--------------------------|-------------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 65021/JPW/AJM/DNS | | Serial No. 08/602,272 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | Applicants: Michael J. Elliot et al. | | | |
| | | | | Filing Date February 26, 1996 | | Group 1642 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Subclass | Translation |
| | | | | | | | Yes No |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| KAC | | Centocor, Inc.'s Remicade (infliximab) Products Webpage, http://www.centocor.com/cgi-in/site/products/prod_remicade.cgi (June 22, 2004) | | | | | |
| | | October 28, 1999 Pharmacological Review for Remicade (infliximab) from the U.S. Food and Drug Administration's Center For Drug Evaluation And Research, http://www.fda.gov/cder/biologics/review/inflcen111099r2.pdf (June 21, 2004) | | | | | |
| | | Label and Approval History for Remicade (infliximab) from the U.S. Food and Drug Administration's Center for Evaluation And Research, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (June 21, 2004) | | | | | |
| EXAMINER | | DATE CONSIDERED | | | | | |
| <i>[Signature]</i> | | <i>9/2/2005</i> | | | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Applicants: Michael J. Elliott, et al.
Serial No.: 08/602,272
Filed: February 16, 1996
Exhibit B